AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

The aim of this collaborative document is to provide an update for clinicians on best
antithrombotic strategies in patients with aortic and/or peripheral arterial diseases …

Patients with peripheral artery disease (PAD) are at an increased risk of major adverse
cardiovascular events, and those with disease in the lower extremities are at risk of major …

Aims This study aimed to analyse the effects of genetic polymorphisms in drug transporters
and metabolizing enzymes, and clinical laboratory data on the pharmacokinetic parameters …

Purpose To investigate risk factors for severe bleeding during warfarin treatment, including
the influence of sex, age, comorbidity and co-medication on bleeding risk. Methods Patients …

Background: The comparative safety and effectiveness of treatments to prevent
thromboembolic complications in atrial fibrillation (AF) remain uncertain. Purpose: To …

The best method of anticoagulation for patients with peripheral artery disease (PAD) is still a
topic of interest for physicians. We conducted a meta-analysis to compare the effects of …

Delayed bleeding is a major and serious adverse event of endoscopic submucosal
dissection (ESD) for early-stage gastrointestinal tumors. The rate of post-ESD bleeding for …

Aims To investigate the effectiveness, safety, and outcomes of lower limb events for non-
vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin among atrial fibrillation (AF) …

Background In patients undergoing revascularization for peripheral arterial disease (PAD),
low-dose Factor Xa inhibitors (FXaI) taken with aspirin improved limb and cardiovascular …